1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
United Therapeutics Corporation

United Therapeutics Corporation

UTHR
United Therapeutics CorporationUS flagNASDAQ Global Select
487.61
USD
-2.63
- -
20.70BMarket Cap

Total Valuation

United Therapeutics Corporation carries a market capitalization of 20.70B, placing it among publicly traded companies globally. Its enterprise value stands at 20.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap20.70B
Enterprise Value20.46B

Share Statistics

United Therapeutics Corporation currently has 42.68M shares outstanding.

Shares Outstanding42.68M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

United Therapeutics Corporation trades at a trailing price-to-earnings ratio of 17.90. The price-to-sales ratio is 7.44, and the price-to-book ratio stands at 3.61.

PE Ratio17.90
PS Ratio7.44
PB Ratio3.61
P/TBV Ratio3.68
P/FCF Ratio11.16
P/OCF Ratio13.92

Enterprise Valuation

On an enterprise value basis, United Therapeutics Corporation trades at an EV/EBITDA multiple of 13.69 and an EV/FCF ratio of 8.95. The EV/Sales ratio of 6.49 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.58 provides insight into valuation relative to core operating earnings.

EV / Sales6.49
EV / EBITDA13.69
EV / EBIT14.58
EV / FCF8.95

Financial Position

United Therapeutics Corporation maintains a current ratio of 5.73, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.

Current Ratio5.73
Quick Ratio4.89
Debt / EquityN/A
Debt / EBITDAN/A
Interest Coverage124.58

Financial Efficiency

United Therapeutics Corporation posts a return on equity of 19.32 and a return on invested capital of 17.23.

Return on Equity (ROE)19.32
Return on Assets (ROA)17.33
Return on Invested Capital (ROIC)17.23
Return on Capital Employed (ROCE)19.46
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.41

Taxes

Over the trailing twelve months, United Therapeutics Corporation has paid 262.10M in income taxes, reflecting an effective tax rate of 16.66.

Income Tax262.10M
Effective Tax Rate16.66

Stock Price Statistics

United Therapeutics Corporation's stock has gained approximately 28.15991% over the past 52 weeks. The 50-day moving average sits at 526.80, while the 200-day moving average is 523.38.

Beta (5Y)N/A
52-Week Price Change28.15991%
50-Day Moving Average526.80
200-Day Moving Average523.38
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, United Therapeutics Corporation generated 3.15B in revenue and converted that into 1.31B in net income, yielding earnings per share of 27.95. EBITDA reached 1.49B, while operating income came in at 1.40B.

Revenue3.15B
Gross Profit2.72B
Operating Income1.40B
Pretax Income1.57B
Net Income1.31B
EBITDA1.49B
EBIT1.40B
Earnings Per Share (EPS)27.95

Balance Sheet

Total book value stands at 6.40B, with working capital of 2.88B providing operational flexibility.

Cash & Cash Equivalents2.66B
Total DebtN/A
Net Debt-1.80B
Equity (Book Value)6.40B
Book Value Per Share149.97
Working Capital2.88B

Cash Flow

United Therapeutics Corporation produced 1.69B in operating cash flow over the past twelve months. After subtracting -592.20M in capital expenditures, free cash flow totaled 1.09B - equivalent to 25.24 per share.

Operating Cash Flow1.69B
Capital Expenditures-592.20M
Free Cash Flow1.09B
FCF Per Share25.24

Margins

United Therapeutics Corporation operates with a gross margin of 86.14, reflecting its pricing power and cost economics. The operating margin of 44.49 and net profit margin of 41.56 provide insight into operational efficiency.

Gross Margin86.14
Operating Margin44.49
Pretax Margin49.87
Profit Margin41.56
EBITDA Margin47.39

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield9.60
FCF Yield8.96

Stock Splits

United Therapeutics Corporation's most recent stock split took place on September 23, 2009 with a 1:2 split ratio.

Last Split Date9/23/2009
Split Ratio1:2

Scores

United Therapeutics Corporation posts an Altman Z-Score of 20.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score20.31